Using IL-1 to enhance treatment for advanced head and neck cancer
IL-1-based immunotherapy in HNSCC
This study is looking at whether adding a special immune booster called interleukin-1 to regular treatments can help people with advanced head and neck cancer feel better and fight the disease more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iowa City VA Medical Center NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11050512 on NIH RePORTER |
What this research studies
This research investigates the use of interleukin-1 (IL-1) as an additional treatment alongside standard therapies for locally advanced head and neck squamous cell carcinoma (HNSCC). The approach aims to harness the immune response triggered by radiation therapy to improve patient outcomes. By combining IL-1 with radiation and chemoradiotherapy, the study seeks to enhance the effectiveness of these treatments in fighting cancer. Patients will be monitored for their immune response and overall health as part of this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with locally advanced head and neck squamous cell carcinoma who are undergoing standard treatment.
Not a fit: Patients with early-stage head and neck cancer or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with advanced head and neck cancer.
How similar studies have performed: While the use of immunotherapy in conjunction with radiation is being explored, this specific approach using IL-1 is novel and has not been extensively tested in prior studies.
Where this research is happening
Iowa City, United States
- Iowa City VA Medical Center — Iowa City, United States (Active)
Researchers
- Principal investigator: Burnett, Andrean Llewela — Iowa City VA Medical Center
- Study coordinator: Burnett, Andrean Llewela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.